IL-7R-alpha SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
AssigneesThe U.S.A., as represented by the Secretary, Department of Health and Human Services, University of Maryland, College Park
InventorsScott Durum, Julie Hixon, Wen Qing Li, Scott Walsh, Lila Kashi
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen binding fragments that specifically bind to IL-7Rα are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7Rα using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7Rα, such as acute lymphoblastic leukemia.
Claims8
A kit comprising
- a) an isolated monoclonal antibody that specifically binds to an extracellular domain of IL-7Rα, or an antigen binding fragment thereof, comprising:
- i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 1 (4A10 VH) and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 2 (4A10 VL);
- or
- ii) a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 3 (2B8 VH) and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 4 (2B8 VL);
- and
- b) instructions for using the kit.
A method of treating a subject with an IL-7Rα-positive cancer in a subject, comprising administering to the subject a therapeutically effective amount of
- a) an isolated monoclonal antibody that specifically binds to an extracellular domain of IL-7Rα, or an antigen binding fragment thereof, comprising:
- i) a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 1 and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 2;
- or
- ii) a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 3 and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 4;
- b) an antibody drug conjugate comprising the monoclonal antibody or antigen binding fragment,
- c) a chimeric antigen receptor (CAR) comprising the antigen binding fragment, or
- d) a T cell expressing the CAR,
- thereby treating the cancer in the subject, wherein the cancer is an acute myeloid leukemia, a chronic myeloid leukemia, a chronic lymphocytic leukemia, a non-Hodgkin lymphoma, a lung cancer, a breast cancer, a pancreatic cancer, a renal cell carcinoma, an adenocarcinoma, or a squamous cell carcinoma.
A method of confirming a diagnosis of cancer in a subject, comprising:
- a) contacting a sample obtained from the subject with effective amount of an isolated monoclonal antibody that specifically binds to an extracellular domain of IL-7Rα, or an antigen binding fragment thereof, comprising:
- i) A VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 1 and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 2;
- or
- ii) a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
- 3 and a VL comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
- 4;
- and
- b) detecting binding of the antibody to the sample, thereby confirming the diagnosis of cancer in a subject.
Dependencies are inferred from the claim text.